CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC

Recruiting Observational Study
Non-Small Cell Lung Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
590 (estimated)
Sponsor
AstraZeneca · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: The following inclusion criteria must be met in order to be enrolled in the stage 1: Patient: * Provide informed consent * 18 years or older * Diagnosed with stage IV NSCLC * Currently receiving or previously received 1L EGFR-TKI treatment * Without communication barrier * Do …
Contacts

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com

CONTACT